| CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (NCT00586391) | Baylor College of Medicine | 2009-02-01 |
| Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (NCT00849654) | Pharmacyclics LLC. | 2009-02-01 |
| R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma (NCT00788606) | Royal Marsden NHS Foundation Trust | 2008-05-01 |
| High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma (NCT00761384) | Lund University Hospital | 2008-04-01 |
| A Study for Patients With Non-Hodgkin's Lymphomas (NCT00542919) | Eli Lilly and Company | 2007-11-01 |
| Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma (NCT00906841) | French Innovative Leukemia Organisation | 2007-10-01 |
| A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma (NCT00486759) | Hoffmann-La Roche | 2007-07-26 |
| Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies (NCT00481871) | Acrotech Biopharma Inc. | 2007-05-01 |
| Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (NCT01300793) | University of California, San Francisco | 2007-05-01 |
| Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant (NCT00434629) | University of Pennsylvania | 2007-02-01 |
| Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) (NCT00299494) | Pfizer | 2006-05-04 |
| Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma (NCT00316511) | Agenus Inc. | 2006-03-01 |
| Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma (NCT00338494) | Yale University | 2005-10-01 |
| An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) (NCT00097929) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Treatment of Aggressive Localized Lymphoma (NCT00841945) | French Innovative Leukemia Organisation | 2005-04-01 |
| Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma (NCT00138086) | Lymphoma Study Association | 2005-03-01 |
| Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma (NCT00169468) | Lymphoma Study Association | 2005-01-01 |
| VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma (NCT00085696) | Millennium Pharmaceuticals, Inc. | 2004-05-01 |
| Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease (NCT00209014) | Emory University | 2003-07-01 |
| PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma (NCT00054665) | National Cancer Institute (NCI) | 2003-02-01 |
| Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer (NCT00001582) | National Cancer Institute (NCI) | 1997-06-07 |
| Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype (NCT00001572) | National Cancer Institute (NCI) | 1997-01-30 |
| Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines (NCT00001512) | National Cancer Institute (NCI) | 1996-09-09 |
| Treatment of Mature B-cell Lymphoma/Leukaemia (NCT00162656) | Gustave Roussy, Cancer Campus, Grand Paris | 1996-05-01 |
| A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma (NCT00001271) | National Cancer Institute (NCI) | 1991-07-01 |